2020
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.
Perazella M. Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary. Kidney360 2020, 1: 166-168. PMID: 35378019, PMCID: PMC8809261, DOI: 10.34067/kid.0001072019.Peer-Reviewed Original Research
2018
Blue-green discoloration of urine and false nephrotic range proteinuria at dipstick urinalysis
Poloni J, de Moraes Sassi M, de Oliveira T, Rotta L, Perazella M. Blue-green discoloration of urine and false nephrotic range proteinuria at dipstick urinalysis. Clinica Chimica Acta 2018, 482: 74-77. PMID: 29608875, DOI: 10.1016/j.cca.2018.03.036.Peer-Reviewed Original ResearchConceptsHigh-power fieldCells/high power fieldLeukocytes/high-power fieldBlue-green discolorationUrine samplesRenal tubular epithelial cellsNephrotic range proteinuriaUrinary tract infectionYear old womanUrine protein concentrationTubular epithelial cellsAlbumin 3Range proteinuriaTract infectionsCellular castsDipstick urinalysisEmergency departmentUrine sedimentBilirubin 2Epithelial cellsPower fieldUrinalysisMethylthioninium chloride
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatients
2009
Acute phosphate nephropathy
Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney International 2009, 76: 1027-1034. PMID: 19675530, DOI: 10.1038/ki.2009.308.Peer-Reviewed Original ResearchConceptsAcute phosphate nephropathyAcute kidney injuryChronic kidney diseasePhosphate nephropathySubsequent chronic renal failureChronic tubular injuryAngiotensin receptor blockersChronic renal failureHigh-risk patientsRenal biopsy findingsClinical-pathological entityAggressive hydrationKidney injuryReceptor blockersBiopsy findingsRenal failureTubular injuryKidney diseasePathological entityRisk factorsFemale genderDistal tubulesEpidemiologic studiesDistal nephronEnzyme inhibitors
2004
Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients
Perazella M, Brewster U, Perazella M. Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients. Seminars In Dialysis 2004, 17: 57-60. PMID: 14717813, DOI: 10.1111/j.1525-139x.2004.17115.x.BooksConceptsInnate immune responseRisk of infectionIntravenous ironEnd-stage renal disease patientsHost innate immune responseRenal disease patientsIron-deficient patientsAdministration of ironOral ironIron therapyMost patientsHemodialysis patientsActive infectionDisease patientsIron preparationsIron overloadAllergic reactionsClinical studiesImmune responsePatientsBacterial infectionsIron deficiencyInfectionRiskBacterial growth
2001
Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs
Perazella M, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. The American Journal Of Medicine 2001, 111: 64-67. PMID: 11448662, DOI: 10.1016/s0002-9343(01)00757-4.Peer-Reviewed Original ResearchCOX-2 Inhibitors and the Kidney
Perazella M. COX-2 Inhibitors and the Kidney. Hospital Practice 2001, 36: 43-56. PMID: 11263799, DOI: 10.3810/hp.2001.03.230.Peer-Reviewed Original ResearchTreatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate
Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella M. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases 2001, 37: 294-299. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.Peer-Reviewed Original ResearchConceptsHigh dialysate calcium concentrationSevere intradialytic hypotensionDialysate calcium concentrationIntradialytic hypotensionBlood pressureEnd-stage renal disease populationCalcium concentrationLow dialysate calciumSeverity of hypotensionMean arterial pressurePeripheral vascular resistanceIntradialytic blood pressureRenal disease populationProspective crossover studyTreatment of patientsMultiple pathogenic factorsType of therapyDialysate calciumHemodynamic instabilityVascular resistanceHemodynamic stabilityArterial pressureCrossover studyCardiac outputCool dialysate
2000
Drug-induced hyperkalemia: old culprits and new offenders
Perazella M. Drug-induced hyperkalemia: old culprits and new offenders. The American Journal Of Medicine 2000, 109: 307-314. PMID: 10996582, DOI: 10.1016/s0002-9343(00)00496-4.Peer-Reviewed Original ResearchConceptsDrug-induced hyperkalemiaRisk of hyperkalemiaRenal potassium excretionRenal impairmentPatient characteristicsPotassium excretionPotassium handlingPotassium loadPrescribed medicationsExcessive ingestionHyperkalemiaCounter drugsOld culpritsNutritional supplementsPotassium homeostasisMedicationsPatientsDrugsCellular uptakeInfusionAbnormalitiesExcretionPhysiciansImpairmentIngestionAce inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitorsAre selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitors
1999
Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem?
Alappan R, Buller G, Perazella M. Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem? American Journal Of Nephrology 1999, 19: 389-394. PMID: 10393376, DOI: 10.1159/000013483.Peer-Reviewed Original ResearchConceptsSerum potassium concentrationSerum creatinine levelsTrimethoprim-sulfamethoxazole therapyBaseline serum potassium concentrationVariety of infectionsCreatinine levelsDay 5Treatment groupsPotassium concentrationControl groupMean serum potassium concentrationBlood urea nitrogen levelsDevelopment of hyperkalemiaLife-threatening hyperkalemiaMild renal insufficiencyDays of therapyHigher serum potassium concentrationsImmunodeficiency syndrome (AIDS) patientsUrea nitrogen levelsSerum glucose concentrationRelevant hyperkalemiaOral antibioticsRenal insufficiencyMost patientsSevere hyperkalemiaMidodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. American Journal Of Kidney Diseases 1999, 33: 920-926. PMID: 10213650, DOI: 10.1016/s0272-6386(99)70427-0.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionPost-HD blood pressuresIntradialytic blood pressureIntradialytic hypotensionBlood pressureEffective therapyLaboratory valuesCombination therapy phaseConsecutive HD treatmentsProspective crossover studyBlood pressure measurementsKt/VVolume of salineControl phaseAlpha1 agonistHypotensive symptomsMorbid complicationCrossover studyUseful therapyProspective studyNursing interventionsHD treatmentMidodrineTreatment phaseTherapy phaseRinger's lactate: An inexpensive and effective dialysate for continuous renal replacement therapy
Perazella M, Cruz D. Ringer's lactate: An inexpensive and effective dialysate for continuous renal replacement therapy. American Journal Of Kidney Diseases 1999, 33: 614-615. PMID: 10070931, DOI: 10.1016/s0272-6386(99)70206-4.Peer-Reviewed Original Research
1998
Malignant Hypertension
Perazella M, Mahnensmith R. Malignant Hypertension. New England Journal Of Medicine 1998, 339: 1985. PMID: 9869670, DOI: 10.1056/nejm199812313392705.Peer-Reviewed Original ResearchLeg Pain and Swelling in an HIV-Infected Drug Abuser
Formica R, Perazella M. Leg Pain and Swelling in an HIV-Infected Drug Abuser. Hospital Practice 1998, 33: 195-197. PMID: 9793550, DOI: 10.1080/21548331.1998.11443771.Peer-Reviewed Original ResearchReduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol
Cayco A, Abu-Alfa A, Mahnensmith R, Perazella M. Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol. American Journal Of Kidney Diseases 1998, 32: 302-308. PMID: 9708617, DOI: 10.1053/ajkd.1998.v32.pm9708617.Peer-Reviewed Original ResearchConceptsDynamic venous pressureHistorical control groupVenous pressureArteriovenous graftsSurveillance protocolStudy groupBlood flow rateThrombosis rateControl groupSimilar historical control groupHemodialysis vascular accessSynthetic arteriovenous graftsLower thrombosis rateML/minGraft impairmentVenous stenosisHD sessionVascular accessVascular stenosisPatientsScreening testStenosisStudy periodFrustrating problemConsecutive readingsMidodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatment
1997
Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients?
Cruz D, Mahnensmith R, Perazella M. Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? American Journal Of Kidney Diseases 1997, 30: 772-779. PMID: 9398120, DOI: 10.1016/s0272-6386(97)90081-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdrenergic alpha-AgonistsAgedAged, 80 and overBlood PressureDiastoleDizzinessFatigueFemaleFollow-Up StudiesHumansHypotensionKidney Failure, ChronicLongitudinal StudiesMaleMiddle AgedMidodrineMuscle CrampMuscle WeaknessParesthesiaProspective StudiesPulseRenal DialysisRisk FactorsSafetyScalpSystoleConceptsDiastolic blood pressureSystolic blood pressureBlood pressureMidodrine therapyArterial pressureHemodialysis patientsIntradialytic hypotensionPulse rateEnd-stage renal disease patientsIntradialytic systolic blood pressureEfficacy of midodrineSymptomatic hemodialysis patientsNeurogenic orthostatic hypotensionMean arterial pressureRenal disease patientsAdequate patient numbersBlood pressure measurementsAlpha-adrenergic agonist activityConsecutive dialysis sessionsAutonomic dysfunctionDialysis hypotensionOral agentsOrthostatic hypotensionSymptomatic hypotensionProspective trialRenal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature.
Cayco A, Perazella M, Hayslett J. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. Journal Of The American Society Of Nephrology 1997, 8: 1788-94. PMID: 9355083, DOI: 10.1681/asn.v8111788.Peer-Reviewed Original ResearchConceptsIntravenous immune globulin therapyAcute renal failureImmune globulin therapyGlobulin therapyRenal replacement therapyNumber of complicationsIVIG treatmentRenal insufficiencyRenal failureRenal injuryIVIG preparationsSuch patientsReplacement therapyClinical disordersTherapyCases recoveryComplicationsPatientsRecurrenceWidespread useInjuryInsufficiencyAgentsCases